HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ANDA Review Time Cuts Possible Without User Fees, Barr Rep Says

This article was originally published in The Tan Sheet

Executive Summary

FDA's Office of Generic Drugs could reduce ANDA review times by adding 50 full time equivalents, Barr Laboratories CEO Bruce Downey told the House Energy & Commerce/Health Subcommittee June 13.

You may also be interested in...

FDA Forced OTC Switch Process Ambiguities Revealed At Subcmte. Hearing

FDA does not have an established procedure in place to prevent the disclosure of protected trade secrets in the event of a forced Rx-to-OTC switch, Center for Drug Evaluation & Research Director Janet Woodcock, MD, told a House panel June 13.

NAPM/GPhA Merger Likely Ends Generic User Fees Push In 107th

The merger agreement between the National Association of Pharmaceutical Manufacturers and the Generic Pharmaceutical Association likely means generic drug user fees will not be a focal point of the PDUFA reauthorization process.

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts